Twelve of thirteen patients were assessable for both CK+ and VIM+ CTC p16 expression changes, indicating that our laboratory-developed test—even with its requirement for tumor marker positivity—detected adequate CK+ CTC numbers (≥ 6) in a higher proportion of patients compared to the 4-channel CellSearch® assay. This evidence concerns the gene CDKN2A and neoplasm.